T. Rowe Price Investment Management, Inc.
Position in AKTS — Aktis Oncology, Inc.
CIK 1897612
BALTIMORE, MD
Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$37,994,996
New position
Shares Held
2,123,812
first reported quarter
Ownership
3.84%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026T. Rowe Price Investment Management, Inc. holds $11,176,949,825 across 48 Biotechnology names. AKTS ranks #31 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
5,193,324 | $1,718,315,111 | |
| 2 | ASND |
Ascendis Pharma A/S
|
6,162,042 | $1,409,443,866 | |
| 3 | CYTK |
Cytokinetics Inc
|
17,523,840 | $1,154,996,294 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
10,300,984 | $867,033,823 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
12,126,017 | $704,642,847 | |
| 6 | DYN |
Dyne Therapeutics, Inc.
|
30,785,801 | $558,146,572 | |
| 7 | BNTX |
BioNTech SE
|
5,856,073 | $520,487,768 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
6,159,027 | $462,481,337 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $37,994,996 | 2,123,812 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||